Skip to main content

BIOFIRE® SPOTFIRE® Vaginitis (VG) Panel*

*Under FDA review. Seeking CLIA waiver. Subject to change. Product not for sale.

1 PCR Test | 8 Results | ~20 Minutes

This multiplex PCR test detects eight results associated with vaginitis in around 20 minutes.

biofire-vaginitis-panel-icon
spotfire-clinic
biofire-spotfire-instrument

Syndromic Vaginitis Testing

Vaginitis affects millions of women every year, yet it is often misdiagnosed since the clinical symptoms overlap.1  Delayed or inappropriate vaginitis treatment is linked to persistent symptoms, high recurrence rates, and serious health consequences, including increased risk of preterm birth and negative effects on intimacy and mental health.2,3

While traditional methods of diagnosis, such as Amsel criteria or Gram stain, remain relevant, they often lack the sensitivity and specificity needed to produce an accurate result, the first time. Conventional lab tests for vaginitis also take time—time that could be saved.4

Ongoing innovation is positioning molecular diagnostics as not just the future of vaginitis testing but also a cornerstone of advancing women's health. Why? Molecular testing is accurate, reliable, and can detect multiple pathogens at once.5

For more information about the limitations of conventional diagnostics and how molecular testing is filling the gap, visit our page here.

The SPOTFIRE VG Panel Testing Menu*

The SPOTFIRE VG Panel is a multiplex PCR test that detects eight results that cause vaginitis, including bacterial vaginosis, candidiasis, and trichomoniasis within 20 minutes.   

Sample type: Self-or-clinician collected vaginal swab in proprietary sample collection kit

Bacteria

Yeast

Protozoa

Bacterial vaginosis (BV)†

  • Atopobium (Fannyhessea) vaginae
  • BVAB2
  • Lactobacillus crispatus
  • Lactobacillus gasseri
  • Lactobacillus jensenii
  • Sneathia sanguinegens/amnii

Candida albicans

Candida glabrata

Candida krusei

Candida parapsilosis

Candida tropicalis

Candida dubliniensis

Trichomonas vaginalis

*Under FDA review. Seeking CLIA waiver. Subject to change. Product not for sale.

†Informed by a proprietary algorithm which returns a binary positive/negative result.

biofire-spotfire-instrument

BIOFIRE® SPOTFIRE® SYSTEM

The SPOTFIRE VG Panel runs on the SPOTFIRE System, a small, scalable, multiplex PCR platform that delivers fast, accurate, and reliable diagnostic results within a point-of-care clinical setting.

  • Requires minimal benchtop space and can be scaled up to four modules vertically, enabling customizable throughput
  • Run up to four tests at the same time thanks to its modular system with random access
  • Easy to use with an intuitive system interface and streamlined workflow
  • Can be used by any healthcare professional in any healthcare setting
  • Seamlessly interfaces with multiple LIS, POC data management systems, and middleware
Click here to learn more about the SPOTFIRE System

References:

  1. Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin (2020) PMID: 31856123 
  2. Mohanty, T., et al. (2023). Effect of bacterial vaginosis on preterm birth: A meta-analysis. Archives of Gynecology and Obstetrics, 308(4), 1247–1255. https://doi.org/10.1007/s00404-022-06817-5 
  3. Chow, K., et al. (2023). Impact of (recurrent) bacterial vaginosis on quality of life and the need for accessible alternative treatments. BMC Women's Health, 23(1), 112. https://doi.org/10.1186/s12905-023-02236-z 
  4. Kong AM, Jenkins D, Troeger KA, Kim G, London RS. Diagnostic Testing of Vaginitis: Improving the Value of Care. Popul Health Manag. 2021 Aug;24(4):515-524. doi: 10.1089/pop.2021.0143. PMID: 34406089. 
  5. Chen J, Tse J, Shi L, Cheng MM, Lillis R, Near AM. Real-world clinical burden of patients presenting with vaginitis symptoms in the United States. AJOG Global Reports. 2025;5:100504. doi:10.1016/j.xagr.2025.100504.